Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

▎药明康德内容团队编辑日前，阿斯利康（AstraZeneca）与安进（Amgen）合作开发的“first-in-class”单抗Tezspire（tezepelumab）针对伴有鼻息肉的慢性鼻窦炎（CRSwNP）患者进行的WAYPOINT临床3期试验 ...

Keywords: Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Biologic therapies, Dupilumab, Omalizumab, Mepolizumab, Reslizumab, Benralizumab, Inflammatory pathways, Biologic treatment efficacy, ...

Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announced Friday that their FDA-approved asthma therapy Tezspire reached ...

AstraZeneca (AZ) and Amgen have shared positive results from a late-stage study of Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The phase 3 WAYPOINT trial ...

The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

公开资料显示，Tezepelumab是阿斯利康与安进共同开发的一款first-in-class单克隆抗体，可抑制胸腺基质淋巴细胞生成素 (TSLP)。TSLP是一种关键的上皮细胞因子，位于多种炎症级联反应的上游，与哮喘、CRSwNP、慢性阻塞性肺疾病 ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...